Other investigated agents include ALK-inhibitors for ALK+ ALCL (crizotinib is already approved for treatment of -children and young adults); PI3K inhibitors, such as duvelisib (NCT03372057), hypomethylating agents – azacytidine or decitabine (NCT04480099, NCT04747236) or immune checkpoint inhibitors (NCT04795869, NCT03278782). Here, ALK is linked to anaplastic large cell lymphoma.